COVID-19
Therapy Areas
Cardio-metabolic & Vascular
COVID-19
Health Security
Influenza & RSV
Oncology
Solutions for
Newsroom
About
Login

INSIGHTS & COMPANY NEWS

Airfinity structures millions of heavily fragmented data points from diverse sources to deliver predictive real-time intelligence. We partner with institutions and organisations to occasionally publish insights we believe are interesting to the broader public.
This page contains a small sample of historic analyses; to access our meta-science platform please contact us.
Airfinity background image landing page
COVID-19 vaccine market forecast to grow 29% to $84.9B in 2022, according to Airfinity

COVID-19 vaccine market forecast to grow 29% to $84.9B in 2022, according to Airfinity

Published by Airfinity

Jan 21, 2022

Our latest analysis predicts that the Pfizer/BioNTech and Moderna vaccines will be the two best selling medical products in 2022
240 million COVID-19 vaccines set to expire by March, according to analysis by Airfinity

240 million COVID-19 vaccines set to expire by March, according to analysis by Airfinity

Published by Airfinity

Jan 13, 2022

Airfinity estimates 241 million COVID-19 vaccine doses purchased by the G7 and EU will go unused and expire by March this year
Airfinity Launches New Influenza and RSV Intelligence Solution

Airfinity Launches New Influenza and RSV Intelligence Solution

Published by Airfinity

Oct 14, 2021

Airfinity's new product provides a single source of truth ​​to monitor the new and upcoming developments on Influenza and RSV.
Pandemic focuses the need for a data-driven antiviral strategy

Pandemic focuses the need for a data-driven antiviral strategy

Published by Airfinity

Jul 22, 2021

The SARS-CoV-2 pandemic has uniquely highlighted the dearth of antiviral compounds that can be readily mobilised and deployed for the treatment of viral diseases.

Document Library

;

Coverage

Sign up to receive the latest insights, product updates and news from Airfinity.

Copyright © Airfinity Limited 2022.
Privacy Policy